Correction: CELLFOOD™ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways (Journal of Experimental & Clinical Cancer Research, (2014), 33, 1, (24), 10.1186/1756-9966-33-24);CELLFOOD™ induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Nuvoli, Barbara ^a   Santoro, Raffaela ^a   Catalani, Simona ^b   Battistelli, Serafina ^b   Benedetti, Serena ^b   Canestrari, Franco ^b   Galati, Rossella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

CELLFOOD (CF); Colorectal cancer; Mesothelioma; Nutraceutical

Indexed keywords

CASPASE 3; CELLFOOD; MYC PROTEIN; NUTRACEUTICAL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HCT116; CELL SURVIVAL; CLONOGENIC ASSAY; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; FIBROBLAST; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

AMINO ACIDS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ENZYMES; HUMANS; MESOTHELIOMA; MINERALS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SULFATES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84898541127     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-022-02498-9     Document Type: Erratum

References (63)

1. The antioxidant protection of CELLFOOD against oxidative damage in vitro. Benedetti S, Catalani S, Palma F, Canestrari F, Food Chem Toxicol 2011 49 2292 2298 10.1016/j.fct.2011.06.029 21703326
2. Efficacy of Cellfood's therapy (deutrosulfazyme) in fibromyalgia. Nieddu ME, Menza L, Baldi F, Frediani B, Marcolongo R, Reumatismo 2007 59 316 321 18157288
3. Metabolism modifications and apoptosis induction after CellfoodTM administration to leukemia cell lines. Catalani S, Carbonaro V, Palma F, Arshakyan M, Galati R, Nuvoli B, Battistelli S, Canestrari F, Benedetti S, J Exp Clin Cancer Res 2013 32 63 10.1186/1756-9966-32-63 24016597
4. A matter of life and death. Green DR, Evan GI, Cancer Cell 2002 1 19 30 10.1016/S1535-6108(02)00024-7 12086884 (Pubitemid 41039172)
5. Cellular survival: a play in three Akts. Datta SR, Brunet A, Greenberg ME, Genes Dev 1999 13 2905 2927 10.1101/gad.13.22.2905 10579998
6. Participation of p53 protein in the cellular response to DNA damage. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW, Cancer Res 1991 51 6304 6311 1933891
7. The regulation and function of the p53 tumor suppressor. Mansur CP, Adv Dermatol 1997 13 121 166 9551143
8. The function of the p53 gene suppressor in carcinogenesis. Sandor J, Ambrus T, Ember I, Orv Hetil 1995 136 1875 1883 7675427
9. Protein modification in aging: an update. Schoneich C, Exp Gerontol 2006 41 807 812 10.1016/j.exger.2006.07.002 17008045 (Pubitemid 44557026)
10. p53, oxidative stress, and aging. Liu D, Xu Y, Antioxid Redox Signal 2011 15 1669 1678 10.1089/ars.2010.3644 21050134
11. p53 in growth control and neoplasia. Gottlieb TM, Oren M, Biochim Biophys Acta 1996 1287 77 102 8672531 (Pubitemid 26189189)
12. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Levy N, Yonish-Rouach E, Oren M, Kimchi A, Mol Cell Biol 1993 13 7942 7952 8247009 (Pubitemid 23354319)
13. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. Vennstrom B, Sheiness D, Zabielski J, Bishop JM, J Virol 1982 42 773 779 6284994 (Pubitemid 12125621)
14. c-MYC: more than just a matter of life and death. Pelengaris S, Khan M, Evan G, Nat Rev Cancer 2002 2 764 776 10.1038/nrc904 12360279 (Pubitemid 37328911)
15. The Myc oncoprotein as a therapeutic target for human cancer. Vita M, Henriksson M, Semin Cancer Biol 2006 16 318 330 10.1016/j.semcancer.2006.07.015 16934487 (Pubitemid 44311040)
16. Reflecting on 25 years with MYC. Meyer N, Penn LZ, Nat Rev Cancer 2008 8 976 990 10.1038/nrc2231 19029958
17. Myc and the cell cycle. Amati B, Alevizopoulos K, Vlach J, Front Biosci 1998 3 250 D268 9468463
18. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Dang CV, Mol Cell Biol 1999 19 1 11 9858526 (Pubitemid 29018404)
19. Control of cell proliferation by Myc family genes. Eilers M, Mol Cells 1999 9 1 6 10102563 (Pubitemid 129620069)
20. The c-MYC-AP4-p21 cascade. Jung P, Hermeking H, Cell Cycle 2009 8 982 989 10.4161/cc.8.7.7949 19270520
21. Myc represses the p21(WAF1/CIP1) promoter and interacts with Sp1/Sp3. Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, Tyner AL, Proc Natl Acad Sci U S A 2001 98 4510 4515 10.1073/pnas.081074898 11274368 (Pubitemid 32295007)
22. Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes. Müller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, Ansorge W, Huttner W, Eilers M, Oncogene 1997 15 2561 2576 10.1038/sj.onc.1201440 9399644 (Pubitemid 27507248)
23. CDK inhibitors: positive and negative regulators of G1-phase progression. Sherr CJ, Roberts JM, Genes Dev 1999 13 1501 1512 10.1101/gad.13.12.1501 10385618 (Pubitemid 29297917)
24. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Strasser A, Harris AW, Bath ML, Cory S, Nature 1990 348 331 333 10.1038/348331a0 2250704 (Pubitemid 120029100)
25. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S, Blood 2003 101 2125 2131 10.1182/blood-2002-06-1714 12424199 (Pubitemid 36302046)
26. Expression of bcl-xL can confer a multidrug resistance phenotype. Minn AJ, Rudin CM, Boise LH, Thompson CB, Blood 1995 86 1903 1910 7655019
27. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, Igawa M, Clin Cancer Res 2006 12 6116 6124 10.1158/1078-0432.CCR-06-0147 17062688 (Pubitemid 44703777)
28. Curcumin induces apoptosis and inhibits growth of human Burkitt's lymphoma in xenograft mouse model. Li ZX, Ouyang KQ, Jiang X, Wang D, Hu Y, Mol Cells 2009 27 283 289 10.1007/s10059-009-0036-9 19326074
29. Antitumor activity of natural compounds, curcumin and PKF118-310, as Wnt/beta-catenin antagonists against human osteosarcoma cells. Leow PC, Tian Q, Ong ZY, Yang Z, Ee PL, Invest New Drugs 2010 28 766 782 10.1007/s10637-009-9311- z 19730790
30. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factorkappaB- regulated gene products. Kunnumakkara AB, Diagaradjane P, Guha S, Deorukhkar A, Shentu S, Aggarwal BB, Krishnan S, Clin Cancer Res 2008 14 2128 2136 10.1158/1078-0432.CCR-07-4722 18381954 (Pubitemid 351551125)
31. Recent advances in chemoprevention of cancer. Hong WK, Sporn MB, Science 1997 278 1073 1077 10.1126/science.278.5340.1073 9353183 (Pubitemid 27517878)
32. What are the critical attributes for cancer chemopreventive agents? Wattenberg LW, Ann NY Acad Sci 1995 768 73 81 10.1111/j.1749-6632.1995.tb12111.x 8526387 (Pubitemid 26078721)
33. How can carcinogenesis be inhibited? Smith TJ, Hong J-Y, Wang Z-Y, Yang CS, Ann NY Acad Sci 1995 768 82 90 10.1111/j.1749-6632.1995.tb12112.x 8526388 (Pubitemid 26078722)
34. Apoptosis as a novel target for cancer chemoprevention. Sun SY, Hail N Jr, Lotan R, J Natl Cancer Inst 2004 96 662 672 10.1093/jnci/djh123 15126603 (Pubitemid 38660229)
35. Down-regulation of the PI3K/Akt signaling pathway and induction of apoptosis in CA46 Burkitt lymphoma cells by baicalin. Huang Y, Hu J, Zheng J, Li J, Wei T, Zheng Z, Chen Y, J Exp Clin Cancer Res 2012 31 48 10.1186/1756-9966-31-48 22607709
36. Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells involving p16 INK4A re-expression related to UHRF1 and DNMT1 down-regulation. Krifa M, Alhosin M, Muller CD, Gies JP, Chekir-Ghedira L, Ghedira K, Mély Y, Bronner C, Mousli M, J Exp Clin Cancer Res 2013 32 30 10.1186/1756-9966-32-30 23688286
37. The role of nutraceuticals in chemoprevention and chemotherapy and their clinical outcomes. Saldanha SN, Tollefsbol TO, J Oncol 2012 2012 192464 22187555
38. On respiratory impairment in cancer cells. Warburg O, Science 1956 124 269 270 13351639
39. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Shannon AM, Bouchier-Hayes DJ, Condron CM, Toomey D, Cancer Treat Rev 2003 29 297 307 10.1016/S0305-7372(03)00003-3 12927570 (Pubitemid 37069660)
40. Hypoxia-a key regulatory factor in tumour growth. Harris AL, Nat Rev Cancer 2002 2 38 47 10.1038/nrc704 11902584 (Pubitemid 37328806)
41. Hypoxia, free radicals and antioxidants. The "Deutrosulfazyme® " paradox. Iorio EL, Hypoxia Med J 2006 1 2 32
42. Cellfood™ improves respiratory metabolism of endothelial cells and inhibits hypoxia-induced reactive oxygen species (ROS) generation. Ferrero E, Fulgenzi A, Belloni D, Foglieni C, Ferrero ME, J Physiol Pharmacol 2011 62 287 293 21893688
43. Localized pleural mesothelioma. The clinical spectrum. Robinson LA, Reilly RB, Chest 1994 106 1611 1615 10.1378/chest.106.5.1611 7956434 (Pubitemid 24346143)
44. Asbestos, the mesothelial cell and malignancy: a matter of life or death. Broaddus VC, Am J Respir Cell Mol Biol 1997 17 657 659 10.1165/ajrcmb.17.6.f141 9409552 (Pubitemid 127348656)
45. World Health Organization, Cancer Incidence in Five Continents Lyon: The World Health Organization and The International Agency for Research on Cancer 2002
46. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Starzynska T, Bromley M, Ghosh A, Stern PL, Br J Cancer 1992 66 558 562 10.1038/bjc.1992.314 1520594
47. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, Neumann-Domer E, Liu Z, Carbone M, Chudoba I, Klein-Szanto AJ, Testa JR, PLoS ONE 2011 6 4 18828 10.1371/journal.pone.0018828 21526190
48. Translocations involving c-myc and c-myc function. Boxer LM, Dang CV, Oncogene 2001 20 5595 5610 10.1038/sj.onc.1204595 11607812 (Pubitemid 32928100)
49. Transcriptional regulation and transformation by Myc proteins. Adhikary S, Eilers M, Nat Rev Mol Cell Biol 2005 6 635 645 10.1038/nrm1703 16064138 (Pubitemid 41081267)
50. Immunoreactivity for c-fos and c-myc protein with the monoclonal antibodies 14E10 and 6E10 in malignant mesothelioma and non-neoplastic mesothelium of the pleura. Ramael M, Van den Bossche J, Buysse C, Deblier I, Segers K, Van Marck E, Histol Histopathol 1995 10 639 643 7579812
51. Overexpression of the c-myc proto-oncogene in colorectal carcinoma is associated with a reduced mortality that is abrogated by point mutation of the p53 tumor suppressor gene. Smith DR, Goh HS, Clin Cancer Res 1996 2 1049 1053 9816266 (Pubitemid 26198474)
52. Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects. Marshall GM, Gherardi S, Xu N, Neiron Z, Trahair T, Scarlett CJ, Chang DK, Liu PY, Jankowski K, Iraci N, Haber M, Norris MD, Keating J, Sekyere E, Jonquieres G, Stossi F, Katzenellenbogen BS, Biankin AV, Perini G, Liu T, Oncogene 2010 29 5957 5968 10.1038/onc.2010.332 20697349
53. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL, Nature 1985 318 533 538 10.1038/318533a0 3906410 (Pubitemid 16173038)
54. Use of transgenic mice to study myc family gene function in normal mammalian development and in cancer. Morgenbesser SD, DePinho RA, Semin Cancer Biol 1994 5 21 36 8186385
55. Making decisions through Myc. Nasi S, Ciarapica R, Jucker R, Rosati J, Soucek L, FEBS Lett 2001 490 153 162 10.1016/S0014-5793(01)02118-4 11223030 (Pubitemid 32171934)
56. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. Oka N, Tanimoto S, Taue R, Nakatsuji H, Kishimoto T, Izaki H, Fukumori T, Takahashi M, Nishitani M, Kanayama HO, Cancer Sci 2006 97 1093 1098 10.1111/j.1349-7006.2006.00294.x 16984382 (Pubitemid 44322559)
57. The Akt inhibitor triciribine sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Dieterle A, Orth R, Daubrawa M, Grotemeier A, Alers S, Ullrich S, Lammers R, Wesselborg S, Stork B, Int J Cancer 2009 125 932 941 10.1002/ijc.24374 19422047
58. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y, Int J Cancer 2005 117 376 380 10.1002/ijc.21170 15900596 (Pubitemid 41429560)
59. Inhibition of the insulin-like growth factor 1 receptor pathway enhances the antitumor effect of cisplatin in human malignant mesothelioma cell lines. Kai K, D'Costa S, Sills RC, Kim J, Cancer Lett 2009 278 49 55 10.1016/j.canlet.2008.12.023 19178995
60. PTEN expression is a strong predictor of survival in mesothelioma patients. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W, Eur J Cardiothorac Surg 2008 33 502 506 10.1016/j.ejcts.2007.09.045 18248818
61. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. Pugazhenthi S, Nesterova A, Sable C, Heidenreich KA, Boxer LM, Heasley LE, Reusch JE, J Biol Chem 2000 275 10761 10766 10.1074/jbc.275.15.10761 10753867 (Pubitemid 30212704)
62. Targeting BCL-2- related proteins in cancer therapy. Manion MK, Hockenbery DM, Cancer Biol Ther 2003 2 105 S114 14508087
63. Plasma membrane localization and function of the estrogen receptor α variant (ER46) in human endothelial cells. Li L, Haynes P, Bender JR, Proc Natl Acad Sci U S A 2003 100 4807 4812 10.1073/pnas.0831079100 12682286 (Pubitemid 36457810)